Charles L. Sawyers

Charles Sawyers is a pioneer in cancer drug development who has made transformative contributions to targeted therapy. His work elucidated mechanisms of imatinib resistance in CML and led to development of second-generation BCR-ABL inhibitors. More recently, he has advanced understanding of prostate cancer biology and treatment resistance.

Charles Sawyers是癌症药物开发的先驱，对靶向治疗做出了变革性贡献。他的工作阐明了CML中imatinib耐药的机制，并导致了第二代BCR-ABL抑制剂的开发。最近，他推进了对前列腺癌生物学和治疗耐药的理解。